Stephen Shafran

414 total citations
15 papers, 315 citations indexed

About

Stephen Shafran is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Stephen Shafran has authored 15 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hepatology, 5 papers in Infectious Diseases and 4 papers in Epidemiology. Recurrent topics in Stephen Shafran's work include Hepatitis C virus research (8 papers), HIV/AIDS drug development and treatment (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Stephen Shafran is often cited by papers focused on Hepatitis C virus research (8 papers), HIV/AIDS drug development and treatment (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Stephen Shafran collaborates with scholars based in Canada, United States and Australia. Stephen Shafran's co-authors include John Conly, Coleman Rotstein, Peter Phillips, Gary Garber, K. Williams, I. W. Fong, Mark Miller, Joel Singer, Fiona Smaill and Irving E. Salit and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Journal of Hepatology.

In The Last Decade

Stephen Shafran

14 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephen Shafran Canada 6 231 199 95 24 20 15 315
Liliana Preoțescu Romania 9 206 0.9× 113 0.6× 153 1.6× 9 0.4× 17 0.8× 25 353
Federica Portunato Italy 9 104 0.5× 50 0.3× 74 0.8× 10 0.4× 24 1.2× 20 214
Mario Magnone United States 6 236 1.0× 85 0.4× 156 1.6× 66 2.8× 7 0.3× 14 364
Nicola Schiano Moriello Italy 11 104 0.5× 159 0.8× 37 0.4× 12 0.5× 17 0.8× 27 266
Luciano M. Vargas United States 8 144 0.6× 67 0.3× 43 0.5× 47 2.0× 23 1.1× 29 413
Francesca Vespasiano Italy 9 75 0.3× 88 0.4× 17 0.2× 20 0.8× 33 1.6× 22 274
E. Vidal Spain 8 210 0.9× 91 0.5× 20 0.2× 17 0.7× 18 0.9× 12 292
Bahadır Ceylan Türkiye 10 144 0.6× 44 0.2× 91 1.0× 47 2.0× 19 0.9× 26 249
Ishani Bora India 7 92 0.4× 142 0.7× 40 0.4× 12 0.5× 5 0.3× 24 256
I Sabaté Spain 8 164 0.7× 40 0.2× 26 0.3× 18 0.8× 70 3.5× 22 332

Countries citing papers authored by Stephen Shafran

Since Specialization
Citations

This map shows the geographic impact of Stephen Shafran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Shafran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Shafran more than expected).

Fields of papers citing papers by Stephen Shafran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Shafran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Shafran. The network helps show where Stephen Shafran may publish in the future.

Co-authorship network of co-authors of Stephen Shafran

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Shafran. A scholar is included among the top collaborators of Stephen Shafran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Shafran. Stephen Shafran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Mangia, Alessandra, Scott Milligan, Mandana Khalili, et al.. (2019). GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. Journal of Hepatology. 70(1). e2–e3. 11 indexed citations
2.
Wyles, David, Alessandra Mangia, Wendy Cheng, et al.. (2017). Long-Term Persistence of HCV NS5A Resistance-Associated Substitutions after Treatment with the HCV NS5A Inhibitor, Ledipasvir, without Sofosbuvir. Antiviral Therapy. 23(3). 229–238. 50 indexed citations
3.
Asselah, Tarik, Stephen Shafran, Sharon Bourgeois, et al.. (2016). Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in HCV Infected Patients Previously Treated with Placebo: Results of the Deferred Treatment Study (GS-US-342-1446 Study). Journal of Hepatology. 64(2). S827–S828. 1 indexed citations
4.
Shafran, Stephen, David Shaw, Kosh Agarwal, et al.. (2016). QUARTZ II-III: Final Efficacy and Safety Results in Patients with HCV Genotype 2 or 3 Infection Treated With Ombitasvir/Paritaprevir/Ritonavir and Sofosbuvir With or Without Ribavirin. Queen Mary Research Online (Queen Mary University of London). 1 indexed citations
5.
6.
Berg, Thomas, Stefan Zeuzem, Christoph P. Berg, et al.. (2013). 792 48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY. Journal of Hepatology. 58. S323–S323. 2 indexed citations
7.
Hall, Jill, Christine Hughes, Michelle Foisy, Stan Houston, & Stephen Shafran. (2013). Iatrogenic Cushing syndrome after intra-articular triamcinolone in a patient receiving ritonavir-boosted darunavir. International Journal of STD & AIDS. 24(9). 748–752. 22 indexed citations
8.
9.
Shafran, Stephen, Barbara R. Conway, Jean Vincelette, et al.. (2002). Field Evaluation of the Merlin Immediate HIV-1 and -2 Test for Point-of-Care Detection of Human Immunodeficiency Virus Antibodies. Clinical Infectious Diseases. 34(5). 658–661. 4 indexed citations
10.
Phillips, Peter, Stephen Shafran, Gary Garber, et al.. (1997). Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. European Journal of Clinical Microbiology & Infectious Diseases. 16(5). 337–345. 172 indexed citations
11.
Conly, John & Stephen Shafran. (1997). Creutzfeldt‐Jakob Disease, New Variant Creutzfeldt‐Jakob Disease and Bovine Spongiform Encephalopathy – An Update. Canadian Journal of Infectious Diseases and Medical Microbiology. 8(1). 15–16. 1 indexed citations
12.
Conly, John & Stephen Shafran. (1995). The Scourge of Tuberculosis Revisited. Canadian Journal of Infectious Diseases and Medical Microbiology. 6(6). 296–297.
13.
Shafran, Stephen & John Conly. (1995). Dash for DOT. Canadian Journal of Infectious Diseases and Medical Microbiology. 6(5). 233–234. 1 indexed citations
14.
Shafran, Stephen & John Conly. (1993). Hepatitis C: Recent Advances. Canadian Journal of Infectious Diseases and Medical Microbiology. 4(4). 195–197. 1 indexed citations
15.
Nicolle, Lindsay E., Jacques Dubois, Alain Martel, et al.. (1993). Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin. Antimicrobial Agents and Chemotherapy. 37(3). 574–579. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liliana Preoțescu Breakdown of academic impact, for papers by Federica Portunato Breakdown of academic impact, for papers by Mario Magnone Breakdown of academic impact, for papers by Nicola Schiano Moriello Breakdown of academic impact, for papers by Luciano M. Vargas Breakdown of academic impact, for papers by Francesca Vespasiano Breakdown of academic impact, for papers by E. Vidal Breakdown of academic impact, for papers by Bahadır Ceylan Breakdown of academic impact, for papers by Ishani Bora Breakdown of academic impact, for papers by I Sabaté
Rankless by CCL
2026